MGTX clears the V9 asymmetry gate with large modeled upside and positive free cash flow despite GAAP losses, but overbought momentum, a string of earnings misses, and notable insider selling temper the setup.
Thesis pillars
- Cash Flow Positive Despite Gaap Loss↑Improving
- High Asymmetry Large Modeled Upside↑Improving
- Consecutive Earnings Misses↑Improving
- +2 more pillars — see the Why tab for full reasoning
MeiraGTx Holdings plc (MGTX) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $14.34, but acceptable to hold if already in. Reasons: Consecutive earnings misses (2); Overbought (RSI 77).
MeiraGTx Holdings is a clinical-stage genetic medicines company developing in vivo gene therapies for salivary gland, neurodegenerative and ocular diseases, manufacturing through its own viral vector facilities in London, UK and Shannon, Ireland. The company earns milestone and... Read more
Hold if already holding. Not a fresh buy at $14.34, but acceptable to hold if already in. Reasons: Consecutive earnings misses (2); Overbought (RSI 77). Chart setup: No clear chart pattern; technical signals are mixed. Quality-value play. Wait for momentum improvement. | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Score 7.0/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 81d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About MeiraGTx Holdings plc
About MeiraGTx Holdings plc
MeiraGTx Holdings develops in vivo gene therapies manufactured at its own viral vector facilities in London, UK and Shannon, Ireland, with a pipeline spanning radiation-induced xerostomia (AAV-hAQP1), Parkinson's disease (AAV-GAD), and inherited retinal disease (AAV-AIPL1, licensed to Eli Lilly). The company reported a net loss of $114.2 million in 2025 against an accumulated deficit of $816.2 million, and held $68.2 million in cash at year-end before an anticipated $150.0 million in additional Hologen funding.
MeiraGTx earns milestone and upfront payments rather than product revenue, having received a $75.0 million upfront payment from Eli Lilly in November 2025 in exchange for exclusive worldwide rights to AAV-AIPL1 and two preclinical ophthalmology candidates, with up to $400.0 million in additional milestones available. In April 2026, the company paid $25.0 million to repurchase rights to its RPGR gene therapy from Janssen Pharmaceuticals, reversing a 2023 sale to Johnson & Johnson Innovative Medicine, while retaining a supply agreement to manufacture commercial RPGR product for J&J with up to $260.0 million in remaining milestones. A March 2025 strategic collaboration with Hologen - expected to close in the second quarter of 2026 - would contribute up to $230.0 million toward the company's neurology programs (AAV-GAD, AAV-BDNF) in exchange for a minority stake in a new joint venture, MeiraGTx Manufacturing, and rights to certain intellectual property.
Show full overview
MeiraGTx's $75.0 million in secured notes to Perceptive Credit Holdings III are collateralized by the company's London and Shannon manufacturing facilities, and the March 2026 amendment pushed the maturity date to May 2027 while requiring a $25.0 million principal redemption by June 30, 2026 - a payment the company expects to fund from cash on hand and the pending Hologen proceeds. Because the same facilities that secure this debt are also the source of MeiraGTx's manufacturing revenue under its J&J supply agreement, any default or acceleration under the Notes Purchase Agreement would directly threaten the collateral base underpinning both the company's commercial manufacturing capacity and its lender relationship.
See also: Healthcare · Biotechnology
From MeiraGTx Holdings plc's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-08-23Recent Developments — MeiraGTx Holdings plc
Latest news
- NEWS Meiragtx CEO Forbes sells $859,320 in company stock By Investing.com - Investing.com Australia — Investing.com Australia negative
- NEWS Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock - MarketBeat — MarketBeat neutral
- NEWS Meiragtx CEO Forbes sells $859,320 in company stock - Investing.com — Investing.com negative
- NEWS MGTX Q2'26 Earnings: EPS estimate is (0.46) USD - TradingView — TradingView negative
- NEWS MGTX Q2'26 Earnings: EPS estimate is (0.46) USD - tradingview.com — tradingview.com neutral
Generated 2026-08-23T02:21:54Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-16Item 1.01MEDIUMMeiraGTx repurchased rights to the RPGR gene-therapy product (X-linked retinitis pigmentosa) from Janssen Pharmaceuticals for a $25.0 million upfront payment plus up to $50.0 million in contingent consideration tied to U.S. regulatory approval and net sales milestones, reversing its 2023 sale of these rights to Johnson & Johnson Innovative Medicine.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $14.34, but acceptable to hold if already in. Reasons: Consecutive earnings misses (2); Overbought (RSI 77). Chart setup: No clear chart pattern; technical signals are mixed. Quality-value play. Wait for momentum improvement. | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Target $25.60 (+78.5%), stop $13.34 (−7.5%), A.R:R 5.2:1. Score 7.0/10, moderate confidence.
Take-profit target: $25.60 (+78.5% upside). Target $25.60 (+78.5%), stop $13.34 (−7.5%), A.R:R 5.2:1. Stop-loss: $13.34.
Consecutive earnings misses (2); Overbought (RSI 77).
MeiraGTx Holdings plc trades at a P/E of 16.7 (forward -10.3). TrendMatrix value score: 8.5/10. Verdict: Hold.
13 analysts cover MGTX with a consensus score of 4.2/5. Average price target: $29.
What does MeiraGTx Holdings plc do?MeiraGTx Holdings is a clinical-stage genetic medicines company developing in vivo gene therapies for salivary gland,...
MeiraGTx Holdings is a clinical-stage genetic medicines company developing in vivo gene therapies for salivary gland, neurodegenerative and ocular diseases, manufacturing through its own viral vector facilities in London, UK and Shannon, Ireland. The company earns milestone and upfront payments from partners including Johnson & Johnson Innovative Medicine (RPGR supply agreement), Eli Lilly ($75.0 million upfront in November 2025 for ophthalmology assets), and Hologen (collaboration expected to close in Q2 2026); it reported a net loss of $114.2 million in 2025.